Cargando…

RADIOTHERAPY OF PROSTATE CANCER: PRIMARY RADIOTHERAPY AND RADIOTHERAPY IN DISEASE RELAPSE

Radiotherapy presents one of the essential modes of treatment in patients with prostate cancer at almost any stage of the disease. It can be delivered as external beam radiotherapy, as brachytherapy or two methods combined. Higher radiation doses are proven to be more effective than low doses and mo...

Descripción completa

Detalles Bibliográficos
Autor principal:	Antunac, Katarina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sestre Milosrdnice University Hospital and Institute of Clinical Medical Research, Vinogradska cesta c. 29 Zagreb 2019
Materias:	Professional Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693550/ https://www.ncbi.nlm.nih.gov/pubmed/34975198 http://dx.doi.org/10.20471/acc.2019.58.s2.08

Ejemplares similares

MRI-GUIDED RADIOTHERAPY FOR PROSTATE CANCER: A NEW PARADIGM
por: Murgić, Jure, et al.
Publicado: (2022)

WHICH PATIENTS SHOULD RECEIVE RADIOTHERAPY IN POSTOPERATIVE DISEASE RECURRENCE?
por: Matić, Mate, et al.
Publicado: (2019)

Stereotactic Body Radiotherapy for Primary Prostate Cancer
por: Kothari, Gargi, et al.
Publicado: (2018)

THE PROSTATE CENTER: MULTIDISCIPLINARITY, ORGANIZATION OF DIAGNOSTIC WORK-UP AND TREATMENT OF PROSTATE CANCER
por: Kuliš, Tomislav, et al.
Publicado: (2019)

THE ROLE OF LYMPHADENECTOMY IN PROSTATE CANCER PATIENTS
por: Markić, Dean, et al.
Publicado: (2019)

Stereotactic ablative radiotherapy for oligometastatic prostate cancer
por: Gallizia, Elena, et al.
Publicado: (2022)

GENOMICS OF PROSTATE CANCER: CLINICAL UTILITY AND CHALLENGES
por: Šamija, Ivan, et al.
Publicado: (2022)

Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer
por: Patel, Priyanka H., et al.
Publicado: (2019)

Safety of image-guided radiotherapy in definitive radiotherapy for localized prostate cancer: a population-based analysis
por: Kuo, Yao-Hung, et al.
Publicado: (2021)

IS TESTOSTERONE PROGNOSTIC IN PROSTATE CANCER TREATMENT? THE UROLOGICAL STANDPOINT.
por: Sorić, Tomislav, et al.
Publicado: (2019)

CHALLENGES IN MANIPULATING IMMUNE SYSTEM TO TREAT PROSTATE CANCER
por: Šamija, Ivan, et al.
Publicado: (2019)

SURGICAL TREATMENT OF HIGH-RISK PROSTATIC CARCINOMA AND OLIGOMETASTATIC DISEASE
por: Mokos, Ivica, et al.
Publicado: (2019)

Complications following surgery with or without radiotherapy or radiotherapy alone for prostate cancer
por: Wallis, C J D, et al.
Publicado: (2015)

Hypofractionated radiotherapy for prostate cancer
por: Hegemann, Nina-Sophie, et al.
Publicado: (2014)

ROLE OF ANDROGEN RECEPTOR-TARGETED AGENTS IN LOCALIZED PROSTATE CANCER
por: Murgić, Jure, et al.
Publicado: (2022)

SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC)
por: Omrčen, Tomislav
Publicado: (2022)

Comparative evaluation of hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate and high risk prostate cancer
por: Soni, Abhishek, et al.
Publicado: (2022)

PROSTATE CANCER DIAGNOSIS IN 2019 - CHANGES IN EUROPEAN GUIDELINES AND IMPACT ON DAILY PRACTICE
por: Tomašković, Igor, et al.
Publicado: (2019)

CURRENT ROLE OF MAGNETIC RESONANCE IMAGING IN THE SCREENING, DIAGNOSIS, AND TREATMENT OF PROSTATE CANCER
por: Nikles, Sven, et al.
Publicado: (2022)

Correlation of High-Sensitivity Cardiac Troponin I Values and Cardiac Radiation Doses in Patients with Left-Sided Breast Cancer Undergoing Hypofractionated Adjuvant Radiotherapy with Concurrent Anti-HER2 Therapy
por: Antunac, Katarina, et al.
Publicado: (2023)

Role of Radiotherapy in Patients With Relapsed Medulloblastoma
por: Lim, Do Hoon
Publicado: (2023)

Qualitative Approach and Treatment of Patients with Prostate Cancer in Cantonal Hospital Bihac During Two Years Period
por: Kardasevic, Amel, et al.
Publicado: (2014)

Radiotherapy is the Preferred Primary Tumor Treatment in Oligometastatic Prostate Cancer
por: van Moorselaar, R. Jeroen A., et al.
Publicado: (2022)

Clinical outcome in metastatic prostate cancer after primary radiotherapy
por: Moll, Matthias, et al.
Publicado: (2022)

The role of salvage brachytherapy for local relapse after external beam radiotherapy for prostate cancer
por: Tisseverasinghe, Steven A., et al.
Publicado: (2018)

Drug Intensification in Future Postoperative Radiotherapy Practice in Biochemically-Relapsing Prostate Cancer Patients
por: Cailleteau, Axel, et al.
Publicado: (2021)

The Prognostic Value of Liquid Biopsies for Benefit of Salvage Radiotherapy in Relapsed Oligometastatic Prostate Cancer
por: Bogdanova, Natalia V., et al.
Publicado: (2022)

WHO SHOULD RECEIVE NOVEL HORMONAL THERAPY WITH ANDROGEN DEPRIVATION THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER?
por: Omrčen, Tomislav
Publicado: (2019)

Review of Hypofractionated Radiotherapy for Prostate Cancer
por: Spyropoulou, Despina, et al.
Publicado: (2012)

Radiotherapy for prostate cancer and sexual health
por: Incrocci, Luca
Publicado: (2015)

Advances in Radiotherapy for Prostate Cancer Treatment
por: Podder, Tarun, et al.
Publicado: (2016)

Cost effectiveness of prostate cancer radiotherapy
por: Konski, Andre
Publicado: (2018)

Intensity-modulated radiotherapy for prostate cancer
por: Fischer-Valuck, Ben W., et al.
Publicado: (2018)

Image-guided radiotherapy for prostate cancer
por: Dang, Audrey, et al.
Publicado: (2018)

The Role of Hypofractionated Radiotherapy in Prostate Cancer
por: Benjamin, Linus C., et al.
Publicado: (2017)

Stereotactic Body Radiotherapy for Prostate Cancer
por: Parikh, Neil R., et al.
Publicado: (2020)

Radiotherapy in nodal oligorecurrent prostate cancer
por: Pinkawa, Michael, et al.
Publicado: (2021)

MR-Guided Radiotherapy for Prostate Cancer
por: Tocco, Boris R., et al.
Publicado: (2020)

Editorial: Advances in radiotherapy for prostate cancer
por: Kamran, Sophia C., et al.
Publicado: (2022)

AMPK activation by AICAR sensitizes prostate cancer cells to radiotherapy
por: Rae, Colin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qu4dg3rbkr4fcajgo6ugfm4sfq